Search

Your search keyword '"Fujinami, Haruka"' showing total 217 results
Start Over Author "Fujinami, Haruka"
217 results on '"Fujinami, Haruka"'

1. Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)

Author

Nagami, Yasuaki, Sakai, Taishi, Yamamura, Masafumi, Nakatani, Masami, Katsuno, Takayuki, Suekane, Takehisa, Uno, Hironori, Minamino, Hiroaki, Okuyama, Masatsugu, Okamoto, Junichi, Kumamoto, Mitsutaka, Noguchi, Atsushi, Yamamori, Kazuki, Takaishi, Osamu, Ochi, Masahiro, Miyazaki, Takako, Tsuji, Shigetsugu, Ikehara, Hisatomo, Kawaguchi, Koichiro, Hayashi, Tomoyuki, Mannami, Tomohiko, Kakimoto, Kazuki, Naito, Yoshihide, Hashimoto, Satoru, Li, Zhaoliang, Komeda, Yoriaki, Kishino, Takaaki, Yamamoto, Yoshinobu, Iguchi, Mikitaka, Akamatsu, Takuji, Horii, Toshiki, Miura, Ko, Yamashina, Takeshi, Sugihara, Yuusaku, Watanabe, Noboru, Kiyotoki, Shu, Fujii, Ryoji, Murata, Masaki, Ono, Satoshi, Narasaka, Toshiaki, Kitamura, Shinji, Kono, Mitsuhiro, Kato, Motohiko, Kawaratani, Hideto, Tanaka, Kyosuke, Yaoita, Takao, Yamaguchi, Shinjiro, Abe, Keiichiro, Kawamura, Takuji, Kinoshita, Yosuke, Imai, Kenichiro, Fujinami, Haruka, Yada, Tomoyuki, Miyamoto, Hayato, Yoshida, Hisako, and Fujiwara, Yasuhiro

Published
2021
Full Text
View/download PDF

4. Efficacy and Safety of Immune Checkpoint Inhibitor Combination Therapy for Dysphagia in Patients with Advanced Esophageal Cancer.

Author

Nakayama, Yurika, Ando, Takayuki, Takagi, Hiroaki, Motoo, Iori, Ueda, Yuko, Sakumura, Miho, Kajiura, Shinya, Takahashi, Saeko, Shimada, Seitaro, Takashima, Yusuke, Fujinami, Haruka, Ogawa, Kohei, Tamura, Hotaka, Hosokawa, Ayumu, and Yasuda, Ichiro

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, CANCER patients, PULMONARY fibrosis, ESOPHAGEAL cancer, OVERALL survival
Abstract

Background/Objectives: Recently, pembrolizumab plus 5-fluorouracil and cisplatin (FP), nivolumab plus FP, and nivolumab plus ipilimumab have become the first-line treatments for patients with advanced esophageal cancer. However, the treatment efficacy in primary tumors has not been reported. We assessed the outcomes of these treatments in advanced esophageal cancer, specifically focusing on esophageal dysphagia improvements and the primary tumor response. Methods: This retrospective study was conducted between October 2021 and November 2023. We investigated 23 patients with esophageal cancer and dysphagia who received an immune checkpoint inhibitor (ICI) plus FP or nivolumab plus ipilimumab. Results: The median progression-free survival (PFS) was 10.6 months (95% confidence interval [CI]: 9.0–12.5), and the median overall survival was not reached (95%CI: 13.0–NA). Improvement in dysphagia was observed in 19/23 (82.6%) patients, with a median time to improvement of 26 days (range: 15–77 days) and a median dysphagia PFS of 12.6 months (range: 8.1–NA months). Ten patients experienced immune-related adverse events (irAEs): seven had interstitial pneumonia, and three had thyroid dysfunction, pituitary dysfunction, and rash, respectively. Conclusions: Although there was a high frequency of irAEs, ICI for esophageal cancer achieved high response rates and prolonged survival. The observed improvement in dysphagia suggests the potential efficacy of the treatment against primary tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer

Author

Ando, Takayuki, primary, Hosokawa, Ayumu, additional, Sakumura, Miho, additional, Motoo, Iori, additional, Kajiura, Shinya, additional, Hirano, Katsuhisa, additional, Miwa, Takeshi, additional, Yokota, Tomotaka, additional, Nakada, Naokatsu, additional, Ueda, Yuko, additional, Ueda, Akira, additional, Tsukada, Kenichiro, additional, Ogawa, Kohei, additional, Nakaya, Atsuko, additional, Teramoto, Akira, additional, Nanjo, Sohachi, additional, Mihara, Hiroshi, additional, Fujinami, Haruka, additional, Fujii, Tsutomu, additional, and Yasuda, Ichiro, additional

Published
2022
Full Text
View/download PDF

20. Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.

Author

Ando, Takayuki, Hosokawa, Ayumu, Sakumura, Miho, Motoo, Iori, Kajiura, Shinya, Hirano, Katsuhisa, Miwa, Takeshi, Yokota, Tomotaka, Nakada, Naokatsu, Ueda, Yuko, Ueda, Akira, Tsukada, Kenichiro, Ogawa, Kohei, Nakaya, Atsuko, Teramoto, Akira, Nanjo, Sohachi, Mihara, Hiroshi, Fujinami, Haruka, Fujii, Tsutomu, and Yasuda, Ichiro

Subjects
STOMACH tumors, ALBUMINS, CLINICAL trials, CONFIDENCE intervals, PATIENT selection, CANCER chemotherapy, MULTIVARIATE analysis, RETROSPECTIVE studies, METASTASIS, TREATMENT effectiveness, RISK assessment, ELIGIBILITY (Social aspects), DESCRIPTIVE statistics
Abstract

Introduction: Third-line chemotherapy has been suggested to improve survival in patients with gastric cancer. This study aimed to identify factors associated with the induction of third-line chemotherapy for advanced gastric cancer, focusing on patient eligibility for clinical trial. Methods: We retrospectively analyzed 335 patients treated for unresectable or recurrent gastric cancer between April 2009 and May 2020. The patients were grouped into those that met the key eligibility criteria for clinical trial (136 patients, 40.6%) and those that did not (199 patients, 59.4%) before receiving first-line chemotherapy. Results: The overall survival (OS) was 16.8 months (95% CI: 14.0–19.6) and 9.3 months (95% CI: 7.8–11.0) in the eligible and ineligible group, respectively. Multivariate analyses to identify the risk factors associated with the induction of third-line chemotherapy revealed ineligibility of clinical trial (OR 1.95; 95% CI: 1.15–3.31), number of metastatic sites (OR 1.99; 95% CI: 1.23–3.22), low albumin concentration (OR 2.24; 95% CI: 1.14–4.38), and a lack of complete or partial response to first-line treatment (OR 1.85; 95% CI: 1.05–3.26). Indeed, in responders to first-line treatment for ineligible patients, the median OS was 17.7 months (95% CI: 10.6–27.9), respectively. Conclusions: Treatment outcomes were different for those eligible for clinical trials and those who were not. However, this study suggested that patients who responded to first-line treatment have more favorable prognosis when treated with salvage chemotherapy, even if they were deemed ineligible for clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. A case of adult-onset type II citrullinemia induced by hospital diet

Author

Ueda, Akira, Okada, Kazuhiko, Takahara, Terumi, Iwasa, Keiichi, Shinagawa, Kazuko, Entani, Akio, Inatsuchi, Syuji, Ando, Takayuki, Fujinami, Haruka, Tajiri, Kazuto, Tokimitsu, Yoshiharu, Ogawa, Kohei, Miyazono, Takayoshi, Miyazaki, Takako, Murakami, Jun, Hosokawa, Ayumu, Yasumura, Satoshi, Minemura, Masami, Kudo, Takahiko, and Sugiyama, Toshiro

Published
2011
Full Text
View/download PDF

26. Additional file 1 of Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)

Author

Nagami, Yasuaki, Taishi Sakai, Yamamura, Masafumi, Nakatani, Masami, Katsuno, Takayuki, Suekane, Takehisa, Uno, Hironori, Minamino, Hiroaki, Masatsugu Okuyama, Okamoto, Junichi, Mitsutaka Kumamoto, Noguchi, Atsushi, Yamamori, Kazuki, Takaishi, Osamu, Ochi, Masahiro, Miyazaki, Takako, Shigetsugu Tsuji, Hisatomo Ikehara, Kawaguchi, Koichiro, Hayashi, Tomoyuki, Mannami, Tomohiko, Kakimoto, Kazuki, Naito, Yoshihide, Hashimoto, Satoru, Zhaoliang Li, Yoriaki Komeda, Kishino, Takaaki, Yamamoto, Yoshinobu, Mikitaka Iguchi, Akamatsu, Takuji, Horii, Toshiki, Miura, Ko, Yamashina, Takeshi, Yuusaku Sugihara, Watanabe, Noboru, Kiyotoki, Shu, Fujii, Ryoji, Murata, Masaki, Ono, Satoshi, Narasaka, Toshiaki, Kitamura, Shinji, Kono, Mitsuhiro, Kato, Motohiko, Kawaratani, Hideto, Tanaka, Kyosuke, Yaoita, Takao, Shinjiro Yamaguchi, Abe, Keiichiro, Kawamura, Takuji, Kinoshita, Yosuke, Imai, Kenichiro, Fujinami, Haruka, Yada, Tomoyuki, Miyamoto, Hayato, Yoshida, Hisako, and Fujiwara, Yasuhiro

Abstract

Additional file 1. Protocol of WHICH study ver. 7.

Published
2021
Full Text
View/download PDF

27. Additional file 2 of Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)

Author

Nagami, Yasuaki, Taishi Sakai, Yamamura, Masafumi, Nakatani, Masami, Katsuno, Takayuki, Suekane, Takehisa, Uno, Hironori, Minamino, Hiroaki, Masatsugu Okuyama, Okamoto, Junichi, Mitsutaka Kumamoto, Noguchi, Atsushi, Yamamori, Kazuki, Takaishi, Osamu, Ochi, Masahiro, Miyazaki, Takako, Shigetsugu Tsuji, Hisatomo Ikehara, Kawaguchi, Koichiro, Hayashi, Tomoyuki, Mannami, Tomohiko, Kakimoto, Kazuki, Naito, Yoshihide, Hashimoto, Satoru, Zhaoliang Li, Yoriaki Komeda, Kishino, Takaaki, Yamamoto, Yoshinobu, Mikitaka Iguchi, Akamatsu, Takuji, Horii, Toshiki, Miura, Ko, Yamashina, Takeshi, Yuusaku Sugihara, Watanabe, Noboru, Kiyotoki, Shu, Fujii, Ryoji, Murata, Masaki, Ono, Satoshi, Narasaka, Toshiaki, Kitamura, Shinji, Kono, Mitsuhiro, Kato, Motohiko, Kawaratani, Hideto, Tanaka, Kyosuke, Yaoita, Takao, Shinjiro Yamaguchi, Abe, Keiichiro, Kawamura, Takuji, Kinoshita, Yosuke, Imai, Kenichiro, Fujinami, Haruka, Yada, Tomoyuki, Miyamoto, Hayato, Yoshida, Hisako, and Fujiwara, Yasuhiro

Subjects
Data_FILES
Abstract

Additional file 2. Statistical analysis plan.

Published
2021
Full Text
View/download PDF

28. Comparison of Histological Sample Volumes among Various Endoscopic Ultrasound-Guided Biopsy Needles

Author

Takahashi, Kosuke, primary, Yasuda, Ichiro, additional, Hanaoka, Tatsuyuki, additional, Hayashi, Yuka, additional, Motoo, Iori, additional, Kajiura, Shinya, additional, Ando, Takayuki, additional, Fujinami, Haruka, additional, Tajiri, Kazuto, additional, Imura, Johji, additional, Ozawa, Eisuke, additional, Miuma, Satoshi, additional, Miyaaki, Hisamitsu, additional, and Nakao, Kazuhiko, additional

Published
2021
Full Text
View/download PDF

29. MO5-1 Characteristics of immune-related adverse events in patients with advanced esophageal cancer treated with nivolumab

Author

Nakada, Naokatsu, primary, Ando, Takayuki, additional, Motoo, Iori, additional, Kajiura, Shinya, additional, Fuchino, Mayo, additional, Sakumura, Miho, additional, Nanjo, Sohachi, additional, Mihara, Hiroshi, additional, Fujinami, Haruka, additional, Ogawa, Kohei, additional, Tsukada, Kenichiro, additional, Nakashima, Koji, additional, Hosokawa, Ayumu, additional, and Yasuda, Ichiro, additional

Published
2021
Full Text
View/download PDF

30. MO5-5 Lesion-level response to immune checkpoint inhibitor in patients with advanced gastric cancer and esophageal cancer

Author

Motoo, Iori, primary, Ando, Takayuki, additional, Murayama, Aiko, additional, Kajiura, Shinya, additional, Ogawa, Kohei, additional, Tsukada, Kenichiro, additional, Ueda, Akira, additional, Suzuki, Nobuhiro, additional, Nakada, Naokatsu, additional, Takatori, Shunsuke, additional, Nakashima, Koji, additional, Hosokawa, Ayumu, additional, Fuchino, Mayo, additional, Nanjo, Sohachi, additional, Fujinami, Haruka, additional, and Yasuda, Ichiro, additional

Published
2021
Full Text
View/download PDF

34. Diagnostic Fine-Needle Biopsy of Small Solid Pancreatic Lesions Using a Franseen Needle during Endoscopic Ultrasound Examination

Author

Takahashi, Kosuke, primary, Yasuda, Ichiro, additional, Hanaoka, Tatsuyuki, additional, Hayashi, Yuka, additional, Araki, Yasuhiro, additional, Motoo, Iori, additional, Kajiura, Shinya, additional, Ando, Takayuki, additional, Fujinami, Haruka, additional, Tajiri, Kazuto, additional, Minemura, Masami, additional, and Takahara, Terumi, additional

Published
2020
Full Text
View/download PDF

37. Continuous Warfarin Administration Versus Heparin Bridging Therapy in Post Colorectal Polypectomy Hemorrhage: A Study Protocol for a Multicenter Randomized Controlled Trial (WHICH Study)

Author

Nagami, Yasuaki, primary, Sakai, Taishi, additional, Yamamura, Masafumi, additional, Nakatani, Masami, additional, Katsuno, Takayuki, additional, Suekane, Takehisa, additional, Uno, Hironori, additional, Minamino, Hiroaki, additional, Okuyama, Masatsugu, additional, Okamoto, Junichi, additional, Kumamoto, Mitsutaka, additional, Noguchi, Atsushi, additional, Yamamori, Kazuki, additional, Takaishi, Osamu, additional, Ochi, Masahiro, additional, Miyazaki, Takako, additional, Tsuji, Shigetsugu, additional, Ikehara, Hisatomo, additional, Kawaguchi, Koichiro, additional, Hayashi, Tomoyuki, additional, Mannami, Tomohiko, additional, Kakimoto, Kazuki, additional, Naito, Yoshihide, additional, Hashimoto, Satoru, additional, Li, Zhaoliang, additional, Komeda, Yoriaki, additional, Kishino, Takaaki, additional, Yamamoto, Yoshinobu, additional, Iguchi, Mikitaka, additional, Akamatsu, Takuji, additional, Horii, Toshiki, additional, Miura, Ko, additional, Yamashina, Takeshi, additional, Sugihara, Yuusaku, additional, Watanabe, Noboru, additional, Kiyotoki, Shu, additional, Fujii, Ryoji, additional, Murata, Masaki, additional, Ono, Satoshi, additional, Narasaka, Toshiaki, additional, Kitamura, Shinji, additional, Kono, Mitsuhiro, additional, Kato, Motohiko, additional, Kawaratani, Hideto, additional, Tanaka, Kyosuke, additional, Yaoita, Takao, additional, Yamaguchi, Shinjiro, additional, Abe, Keiichiro, additional, Kawamura, Takuji, additional, Kinoshita, Yosuke, additional, Imai, Kenichiro, additional, Fujinami, Haruka, additional, Yada, Tomoyuki, additional, Miyamoto, Hayato, additional, Yoshida, Hisako, additional, and Fujiwara, Yasuhiro, additional

Published
2020
Full Text
View/download PDF

38. Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea

Author

Sakumura, Miho, primary, Ando, Takayuki, additional, Hosokawa, Ayumu, additional, Nakajima, Takahiko, additional, Motoo, Iori, additional, Mihara, Hiroshi, additional, Ueda, Akira, additional, Kajiura, Shinya, additional, Nanjo, Sohachi, additional, Fujinami, Haruka, additional, Ogawa, Kohei, additional, and Yasuda, Ichiro, additional

Published
2020
Full Text
View/download PDF

42. The potential diagnostic significance of crypt differentiation in gastric dysplasia.

Author

Nakajima, Takahiko, Noguchi, Akira, Tanaka, Shinichi, Nishida, Takeshi, Hatta, Hideki, Kakiuchi, Toshiko, Takagi, Kohji, Minamisaka, Takashi, Fujinami, Haruka, Yoshizumi, Tetsuya, and Imura, Johji

Subjects
CANCER invasiveness, DYSPLASIA, NEUROENDOCRINE cells, CELL differentiation, GASTRIC mucosa, INTESTINAL mucosa
Abstract

Aims: This study investigated the relationship between the differentiation of tumour cells into crypts, which is determined by cell differentiation into Paneth and neuroendocrine cells, and tumour infiltration in gastric dysplasia. Methods and results: The lesions were endoscopically biopsied low‐grade dysplasia (LGD), endoscopically resected high‐grade dysplasia (HGD) or cancer with submucosal invasion. LGD (n = 32) displayed crypt differentiation across the entire width of the tumour in all cases. Crypt differentiation was identified as a characteristic of tumours with low biological malignancy. HGD (n = 40) included tumours with a mixture of areas with and without crypt differentiation (n = 25) and tumours with crypt differentiation throughout the entire width (n = 15). Of the cancers with submucosal invasion (n = 30), the morphological progression of the HGD area with crypt differentiation, the HGD area without crypt differentiation and invasive cancer without crypt differentiation was confirmed for 23 samples. In two lesions, invasive cancer without crypt differentiation developed from HGD without crypt differentiation throughout the tumour width. In five samples, well‐differentiated tubular adenocarcinoma with crypt differentiation developed from HGD with crypt differentiation and invaded with lamina propria‐like stroma. Conclusions: Loss of crypt differentiation could be an objective indicator of infiltration in the progression of HGD to invasive cancer. The invasive potential of dysplasia depends upon the presence or absence of crypt differentiation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with direct oral anticoagulants or warfarin

Author

Matsubara, Yuki, primary, Ando, Takayuki, additional, Sakumura, Miho, additional, Yoshita, Hiroki, additional, Nanjo, Sohachi, additional, Mihara, Hiroshi, additional, Fujinami, Haruka, additional, Tsukada, Kenichiro, additional, Shinya, Kajiura, additional, Ogawa, Kohei, additional, Hosokawa, Ayumu, additional, Terada, Mitsuhiro, additional, and Yasuda, Ichiro, additional

Published
2019
Full Text
View/download PDF

46. Multiple Synchronous Sporadic Gastrointestinal Stromal Tumors in the Stomach and Jejunum

Author

Tokunaga, Mami, primary, Nanjo, Sohachi, additional, Yoshita, Hiroki, additional, Fujinami, Haruka, additional, Watanabe, Tohru, additional, Ishii, Yoko, additional, Kobayashi, Saito, additional, Akashi, Momoko, additional, Takagi, Hiroaki, additional, Mihara, Hiroshi, additional, Kajiura, Shinya, additional, Ando, Takayuki, additional, Hashimoto, Isaya, additional, Hojo, Shozo, additional, Okumura, Tomoyuki, additional, and Sugiyama, Toshiro, additional

Published
2018
Full Text
View/download PDF

48. MOESM1 of The influence of duodenally-delivered Shakuyakukanzoto (Shao Yao Gan Cao Tang) on duodenal peristalsis during endoscopic retrograde cholangiopancreatography: a randomised controlled trial

Author

Fujinami, Haruka, Kajiura, Shinya, Nishikawa, Jun, Ando, Takayuki, and Sugiyama, Toshiro

Subjects
ComputingMilieux_THECOMPUTINGPROFESSION, Data_FILES, ComputingMilieux_LEGALASPECTSOFCOMPUTING, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Additional file 1. Approval of ethics committee.

Published
2017
Full Text
View/download PDF

49. Mucosal injury of small intestine in patients with advanced gastric cancer who developed chemotherapy induced diarrhea (CID).

Author

Sakumura, Miho, primary, Ando, Takayuki, additional, Hosokawa, Ayumu, additional, Mihara, Hiroshi, additional, Takagi, Hiroaki, additional, Yoshita, Hiroki, additional, Nanjo, Sohachi, additional, Ueda, Akira, additional, Fujinami, Haruka, additional, Kajiura, Shinya, additional, Ogawa, Kohei, additional, and Sugiyama, Toshiro, additional

Published
2018
Full Text
View/download PDF

50. Baseline factors associated with acute progression of metastatic lesions after primary tumor resection in patients with unresectable colorectal cancer.

Author

Akashi, Momoko, primary, Ando, Takayuki, additional, Hosokawa, Ayumu, additional, Yoshita, Hiroki, additional, Nanjyo, Sohachi, additional, Ueda, Akira, additional, Mihara, Hiroshi, additional, Fujinami, Haruka, additional, Kajiura, Shinya, additional, Ogawa, Kohei, additional, and Sugiyama, Toshiro, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results